Singapore markets open in 1 hour 51 minutes

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.77000.0000 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 8.27M
Enterprise value 694.79k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)55.50
Price/book (mrq)0.73
Enterprise value/revenue -655.82
Enterprise value/EBITDA -0.07

Trading information

Stock price history

Beta (5Y monthly) 1.83
52-week change 3-46.49%
S&P500 52-week change 325.01%
52-week high 36.7500
52-week low 31.7500
50-day moving average 33.1162
200-day moving average 33.2169

Share statistics

Avg vol (3-month) 32.93k
Avg vol (10-day) 33.07k
Shares outstanding 52.71M
Implied shares outstanding 62.71M
Float 81.13M
% held by insiders 120.77%
% held by institutions 141.34%
Shares short (28 Mar 2024) 422.05k
Short ratio (28 Mar 2024) 49.25
Short % of float (28 Mar 2024) 41.11%
Short % of shares outstanding (28 Mar 2024) 40.81%
Shares short (prior month 29 Feb 2024) 424.7k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 316 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-38.34%
Return on equity (ttm)-115.85%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-12.59M
Diluted EPS (ttm)-5.3900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.57M
Total cash per share (mrq)2.98
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.85
Book value per share (mrq)4.56

Cash flow statement

Operating cash flow (ttm)-21.25M
Levered free cash flow (ttm)-9.52M